Find therapies in clinical trials near you – page 15

Study of Chemotherapy vs. Nivolumab for Patients with Resectable Non-Small Cell Lung Cancer

Study of Chemotherapy vs. Nivolumab for Patients with Resectable Non-Small Cell Lung Cancer

Study of Nivolumab and Ipilimumab with Chemotherapy for Patients with Stage IV Non-Small Cell Lung Cancer and Brain Metastases

Study of Nivolumab and Ipilimumab with Chemotherapy for Patients with Stage IV Non-Small Cell Lung Cancer and Brain Metastases

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Study Comparing Chemotherapy Alone to Chemotherapy with Nivolumab or Nivolumab and BMS-986205 for Patients with Muscle-Invasive Bladder Cancer

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Study of BMS-986012, carboplatin, etoposide and nivolumab combination as first treatment for patients with extensive-stage small cell lung cancer

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with BRAF V600E/K Mutation-Positive Melanoma After Anti-PD-1 Therapy

Study of Chemotherapy and Nivolumab for Patients with Locally Advanced Non-Small Cell Lung Cancer

Study of Chemotherapy and Nivolumab for Patients with Locally Advanced Non-Small Cell Lung Cancer

Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

Study of LN-144 and LN-145 (Tumor Infiltrating Lymphocytes) in patients with solid tumors, including melanoma, head and neck cancer, and non-small cell lung cancer

Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Study of Nivolumab and Relatlimab for Patients with Resectable Non-Small Cell Lung Cancer

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Study on the Effects of Pembrolizumab, Atezolizumab, and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer

Study on the Effects of Pembrolizumab, Atezolizumab, and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation